Fosbretabulin (DB12577): A Comprehensive Monograph on a Vascular-Disrupting Agent in Oncology

Executive Summary

Fosbretabulin, also known as Combretastatin A-4 Phosphate (CA4P), is an investigational small molecule drug that represents a distinct class of anticancer agents known as Vascular-Disrupting Agents (VDAs). Originating as a water-soluble prodrug of combretastatin A4, a natural compound from the African bush willow, Combretum caffrum, Fosbretabulin was engineered to overcome the pharmaceutical limitations of its parent compound. Its mechanism of action is both potent and unique, centered on a dual-pronged attack against the tumor vasculature. Primarily, its active metabolite, combretastatin A4, binds to the colchicine site of β-tubulin, leading to rapid depolymerization of the microtubule cytoskeleton in immature endothelial cells. This is complemented by a secondary mechanism involving the disruption of VE-cadherin-mediated cell junctions. The synergistic result is a swift and catastrophic collapse of tumor blood vessels, leading to acute ischemia and extensive necrosis within the tumor core.

Preclinical models demonstrated remarkable efficacy, with single doses causing near-total shutdown of tumor blood flow within hours. However, these studies also revealed a critical limitation: the survival of a peripheral "rim" of viable tumor cells, which invariably led to regrowth. This single observation has fundamentally shaped the drug's clinical development, mandating a strategic focus on combination therapies designed to target this surviving fraction.

Clinically, Fosbretabulin has been investigated across a range of solid tumors, including anaplastic thyroid carcinoma (ATC), recurrent ovarian cancer, non-small cell lung cancer (NSCLC), and neuroendocrine tumors (NETs), reaching as far as Phase III trials. Despite its compelling mechanism, the clinical results have been challenging. In a pivotal Phase II trial for recurrent ovarian cancer (GOG-186I), the combination of Fosbretabulin with bevacizumab met its primary endpoint of improving progression-free survival (PFS). However, this benefit did not translate into an improvement in the gold-standard endpoint of overall survival (OS), a discordance that significantly complicates the path to regulatory approval. Trials in other indications have similarly failed to demonstrate a clear survival advantage.

The drug's safety profile is characterized by on-target toxicities that are a direct consequence of its potent vascular-disrupting effects. Acute, transient hypertension and QTc interval prolongation are the most common and dose-limiting cardiovascular adverse events. These toxicities create a narrow therapeutic window, making the drug difficult to manage and constraining its use in combination regimens.

Fosbretabulin's regulatory journey reflects these clinical challenges. While it holds an Orphan Drug Designation from the U.S. FDA for neuroendocrine tumors, it remains unapproved. In Europe, multiple orphan designations granted by the EMA for ATC, ovarian cancer, and GEP-NETs were subsequently withdrawn at the sponsor's request. This pattern strongly suggests an internal assessment that the drug would be unable to demonstrate "significant benefit" over evolving standards of care.

In conclusion, Fosbretabulin is a mechanistically elegant VDA whose potent preclinical activity has not translated into a compelling clinical benefit-risk profile. Hampered by a narrow therapeutic index, a consistent failure to improve overall survival, and a challenging regulatory landscape, its future in oncology appears limited. It serves as a valuable, albeit cautionary, example of the profound difficulties in translating a powerful anti-vascular strategy into a successful therapeutic for cancer patients.

Section 1: Foundational Profile and Pharmacological Basis

The scientific rationale for Fosbretabulin is rooted in its unique chemical identity as a prodrug and its sophisticated, dual-pronged attack on the tumor microenvironment. Its development represents a strategic effort to harness the potent antivascular properties of a natural product by overcoming its inherent pharmaceutical liabilities. This section details the chemical foundation, the intricate mechanism of action, and the compelling preclinical data that propelled Fosbretabulin into clinical investigation.

1.1. Chemical Identity and Physicochemical Properties

Fosbretabulin is a synthetic, small molecule drug classified as an antineoplastic agent.[1] Its development was driven by the need to create a clinically viable form of combretastatin A4 (CA4), a stilbenoid phenol originally isolated from the bark of the South African bush willow,

Combretum caffrum.[1] While CA4 demonstrated potent antitumor activity, its clinical utility was severely hampered by poor aqueous solubility and the chemical instability of its biologically active

(Z)- or cis-isomer, which can readily convert to the far less active (E)- or trans-isomer.[6]

To address these limitations, a phosphate group was added to the parent molecule, creating the water-soluble prodrug Fosbretabulin.[1] This chemical modification is not merely a formulation enhancement but the central innovation that enables the drug's therapeutic concept. The high water solubility allows for intravenous administration and rapid systemic distribution, which is essential for an agent designed to induce an acute vascular effect. Following administration, endogenous phosphatases

in vivo rapidly cleave the phosphate group, releasing the active, lipophilic metabolite, combretastatin A4, systemically to exert its effects on the tumor vasculature.[1] To further improve its pharmaceutical properties for clinical use, Fosbretabulin is formulated as either a disodium or tromethamine salt.[3]

Table 1: Identification and Chemical Properties of Fosbretabulin

Property	Value	Source(s)
Generic Name	Fosbretabulin	2
Common Synonyms	Combretastatin A-4 phosphate, CA4P, CA4PD, Phosbretabulin	1
US Brand Name	ZYBRESTAT	3
DrugBank ID	DB12577	1
CAS Number	222030-63-9	1
IUPAC Name	[2-methoxy-5-[(Z)-2-(3,4,5-trimethoxyphenyl)ethenyl]phenyl] dihydrogen phosphate	1
Molecular Formula	C18​H21​O8​P	1
Molar Mass	396.332 g·mol⁻¹	9
Chemical Class	Stilbene, Benzene Derivative, Benzylidene Compound	2
Key Structural Features	Water-soluble phosphate prodrug of combretastatin A4; retains the active (Z)-stilbene configuration	1

1.2. Pharmacodynamics: A Dual-Pronged Mechanism of Vascular Disruption

Fosbretabulin is the lead compound in a class of drugs known as Vascular-Disrupting Agents (VDAs), which are designed to attack and destroy the established blood vessels within a tumor, rather than preventing the formation of new ones (the mechanism of anti-angiogenic agents).[9] The speed and magnitude of its effect are attributable to a synergistic, dual-pronged mechanism that simultaneously dismantles the internal cytoskeletal structure of endothelial cells and severs the junctions that bind them together.

1.2.1. Primary Mechanism: Microtubule Destabilization

The principal mechanism of action of Fosbretabulin's active metabolite, CA4, is the potent inhibition of microtubule polymerization.[1] CA4 binds with high affinity (dissociation constant,

Kd​, of 0.4 μM) to the colchicine-binding site on the β-tubulin subunit of tubulin dimers.[10] This interaction prevents the assembly of these dimers into functional microtubules, which are essential components of the cellular cytoskeleton.[3] The half-maximal inhibitory concentration (

IC50​) for tubulin polymerization is 2.4 μM.[12]

This microtubule-destabilizing effect is particularly devastating to the endothelial cells lining the neovasculature of solid tumors. Unlike the mature, stable blood vessels found in healthy tissues, tumor blood vessels are often chaotic, tortuous, and structurally immature. They are inadequately supported by pericytes and smooth muscle cells and are therefore highly dependent on their internal microtubule network to maintain their flattened shape and structural integrity.[7] By disrupting this critical internal scaffolding, CA4 induces rapid and profound changes in endothelial cell morphology, causing them to round up and detach from the vessel wall. This process also leads to cell cycle arrest in the G2/M phase and triggers apoptosis.[1]

1.2.2. Secondary Mechanism: Disruption of Endothelial Cell Junctions

Complementing its direct assault on the cytoskeleton, CA4 also targets the intercellular "mortar" that holds the endothelial cells together. It disrupts the function of vascular endothelial-cadherin (VE-cadherin), an endothelial cell-specific junctional molecule crucial for maintaining the integrity of the vascular wall.[3] Specifically, this action inhibits the VE-cadherin/β-catenin/Akt signaling pathway, which is vital for endothelial cell survival, migration, and capillary formation.[3]

The downstream consequences of this pathway disruption are manifold. It leads to the formation of actin stress fibers and membrane blebbing via activation of the Rho/Rho-kinase pathway, further compromising cell structure.[12] Crucially, it causes a rapid increase in the permeability of the endothelial monolayer, effectively making the tumor blood vessels leaky and dysfunctional.[3]

1.2.3. Synergistic Outcome: Vascular Collapse and Ischemic Necrosis

The combination of these two mechanisms creates a powerful synergistic effect. The simultaneous attack on both the endothelial cells' internal structure (microtubules) and their external connections (VE-cadherin junctions) leads to a swift and catastrophic failure of the tumor vasculature.[1] This rapid "vascular shutdown" acutely deprives the tumor of its essential supply of oxygen and nutrients. The result is extensive and rapid ischemic necrosis, particularly in the central core of the tumor, which is often poorly perfused and resistant to conventional therapies.[1] This effect occurs within minutes to hours of drug administration and is remarkably selective for the abnormal tumor vasculature, largely sparing the more robust and mature vasculature of healthy tissues.[5]

1.3. Preclinical Evidence of Antitumor Activity

Extensive preclinical research provided a strong foundation for the clinical development of Fosbretabulin, demonstrating its potent activity both in vitro and in vivo.

1.3.1. In Vitro Potency

Fosbretabulin, administered as its active form CA4P, has shown significant antiproliferative activity against a wide array of human cancer cell lines in laboratory assays. The potency varies by cell line but is often in the low nanomolar to low micromolar range. For example, it demonstrated a half-maximal growth inhibition (GI50​) of 2.82 nM against NCI-H460 non-small cell lung cancer cells and a half-maximal inhibitory concentration (IC50​) of 4.7 nM against HeLa cervical cancer cells and 4.5 nM against SKOV3 ovarian cancer cells.[11] Its activity against endothelial cells was demonstrated with an

IC50​ of 6.4 μM against the EA.hy926 endothelial cell line.[11]

1.3.2. In Vivo Vascular Disruption

Animal models provided dramatic proof-of-concept for the VDA mechanism. In tumor-bearing mice, the administration of a single dose of CA4P, at levels as low as 10% of the maximum tolerated dose (MTD), was shown to cause rapid, extensive, and irreversible vascular shutdown within the tumor.[12] Quantitative imaging studies documented a staggering 93% reduction in functional vascular volume and an approximately 100-fold reduction in tumor blood flow just 6 hours after drug administration.[12] This profound anti-vascular effect was highly selective, with blood flow in healthy organs like the spleen being reduced by only 7-fold in comparison.[12]

1.3.3. The "Viable Rim" Phenomenon: A Critical Limitation

Despite the impressive induction of central tumor necrosis, a consistent and critical observation in preclinical models was the survival of a thin, peripheral rim of viable tumor cells.[5] This rim is believed to be sustained by its proximity to the more stable vasculature of adjacent normal tissue, which is less susceptible to the drug's effects. This surviving population of cells is capable of re-establishing vascular supply and driving tumor regrowth following treatment.[10]

The existence of this viable rim represents the fundamental Achilles' heel of VDA monotherapy. It predicts that while Fosbretabulin can cause dramatic tumor shrinkage, it is unlikely to be curative on its own. This single preclinical finding has been the primary driver of Fosbretabulin's clinical development strategy, providing a compelling biological rationale for investigating it in combination with other therapeutic modalities. The logical partners are agents that can effectively target the proliferating cells in this surviving rim, such as conventional chemotherapy or anti-angiogenic agents designed to prevent the revascularization process.[5] The entire clinical narrative of Fosbretabulin is thus a direct consequence of this crucial preclinical limitation.

Section 2: Clinical Efficacy Across Investigated Indications

The clinical development program for Fosbretabulin has been extensive, spanning multiple tumor types and therapeutic strategies, from monotherapy in rare, aggressive cancers to combination regimens with chemotherapy and other targeted agents. This section provides a critical evaluation of the key clinical trials, analyzing the data to understand the drug's performance in the context of its mechanism and the specific diseases investigated.

Table 2: Summary of Key Clinical Trials of Fosbretabulin

Trial Identifier	Phase	Indication	Treatment Regimen(s)	No. of Patients	Primary Endpoint
NCT00060242	II	Anaplastic Thyroid Carcinoma	Fosbretabulin Monotherapy	26	Objective Response Rate
GOG-186I (NCT01305213)	II	Recurrent Ovarian Cancer	Bevacizumab +/- Fosbretabulin	107	Progression-Free Survival (PFS)
NCT00653939	II	Non-Small Cell Lung Cancer	Carboplatin + Paclitaxel + Bevacizumab +/- Fosbretabulin	63	Safety
PAZOFOS (NCT02055690)	Ib/II	Recurrent Ovarian Cancer	Pazopanib +/- Fosbretabulin	N/A	Recommended Phase II Dose / PFS
NCT03014297	I	Neuroendocrine Tumors	Everolimus + Fosbretabulin	17	Maximum Tolerated Dose

2.1. Anaplastic Thyroid Carcinoma (ATC): An Initial Hope

Anaplastic thyroid carcinoma is one of the most lethal human malignancies, accounting for only 1-2% of thyroid cancers but causing a disproportionately high mortality rate, with a historical median survival of only 4-6 months.[17] The lack of effective therapies made ATC a logical and high-unmet-need target for a novel agent like Fosbretabulin.[9] Initial optimism was fueled by a case report from an early Phase I trial where a patient with ATC experienced a durable complete response lasting over nine years after receiving Fosbretabulin monotherapy.[16]

This led to the initiation of a multicenter Phase II trial (NCT00060242), one of the largest prospective studies ever conducted in this rare disease.[16] The trial enrolled 26 patients with advanced ATC who received Fosbretabulin at a dose of 45 mg/m² intravenously on days 1, 8, and 15 of a 28-day cycle.[17] The primary objective was to determine if the drug could double the median survival time.[17]

Despite the promising preclinical rationale, the trial failed to meet its primary endpoint. No objective tumor responses (complete or partial) were observed, and the median overall survival was 4.7 months, showing no significant improvement over the historical baseline.[17] However, the results were not entirely negative and contained nuances that suggested some level of biological activity. A notable portion of patients survived longer than expected, with 34% alive at 6 months and 23% alive at 12 months. Furthermore, seven patients (27%) achieved stable disease, which was maintained for a median duration of 12.3 months (range, 4.4-37.9 months).[17] This suggests that while Fosbretabulin did not induce tumor shrinkage, it may have provided a meaningful disease stabilization benefit for a subset of patients.

The trial also yielded two intriguing but preliminary findings from correlative science. First, an analysis of baseline serum levels of soluble intracellular adhesion molecule-1 (sICAM-1), a marker of endothelial activation, revealed that patients in the lowest tertile of sICAM-1 levels had a significantly better event-free survival (p<0.009).[16] This finding proposed sICAM-1 as a potential prognostic or predictive biomarker for VDA therapy, though it requires prospective validation. Second, a later retrospective review identified two separate long-term ATC survivors (living 8 and 10 years) who had received Fosbretabulin-based regimens.[20] A common feature in both cases was the presence of profound hypothyroidism, with markedly elevated thyroid-stimulating hormone (TSH) levels. This observation led to the hypothesis that hypothyroidism might correlate with improved outcomes in ATC patients treated with Fosbretabulin, though the biological basis for such a link remains speculative.[20] These findings represent unrealized potential, highlighting the immense difficulty of validating biomarkers and correlative signals in rare diseases where large patient cohorts are impossible to assemble.

2.2. Recurrent Ovarian Cancer: The Combination Strategy

The clinical strategy for Fosbretabulin in ovarian cancer was directly informed by the "viable rim" hypothesis derived from preclinical studies. The rationale was to combine the VDA Fosbretabulin, which destroys the core tumor vasculature, with the anti-angiogenic agent bevacizumab, which inhibits the formation of new blood vessels needed for the surviving rim to regrow. This complementary "one-two punch" was designed to produce a more durable antitumor effect than either agent alone.[10]

This strategy was tested in the Gynecologic Oncology Group (GOG) 186-I trial (NCT01305213), a randomized, open-label Phase II study.[21] The trial enrolled 107 patients with recurrent or persistent ovarian, fallopian tube, or primary peritoneal cancer who had received one to three prior chemotherapy regimens. Patients were randomized to receive either bevacizumab (15 mg/kg IV every 3 weeks) alone or bevacizumab in combination with Fosbretabulin (60 mg/m² IV every 3 weeks).[21]

The study successfully met its primary endpoint of improving progression-free survival (PFS).[21] The combination of Fosbretabulin and bevacizumab resulted in a clinically meaningful and statistically significant delay in disease progression compared to bevacizumab alone. However, this success was tempered by the lack of a corresponding benefit in overall survival (OS), the definitive measure of clinical benefit. This "PFS-OS discordance" is a significant challenge in oncology drug development, as it raises questions about whether a drug is truly altering the natural history of the disease or merely delaying radiographic progression without making patients live longer. For regulators and clinicians, a PFS benefit without an OS benefit, especially when accompanied by added toxicity, often represents an unfavorable risk-benefit balance.

Table 3: Efficacy Results of the GOG-186I Trial (NCT01305213) in Recurrent Ovarian Cancer

Efficacy Endpoint	Bevacizumab + Fosbretabulin Arm	Bevacizumab Alone Arm	Hazard Ratio (HR) / p-value	Source(s)
Median PFS (Primary)	7.3 months	4.8 months	HR: 0.69 (one-sided p=.05)	14
Median PFS (Extended Follow-up)	7.6 months	4.8 months	HR: 0.74	24
Median OS	25.2 months	24.4 months	HR: 0.85 (p=0.461)	24
Overall Response Rate (ORR)	35.7%	28.2%	Relative Probability: 1.27 (p=.24)	21
Post-Hoc Analysis by Tumor Size
Median PFS (Tumors ≤5.7 cm)	N/A	N/A	HR: 0.77	24
Median PFS (Tumors >5.7 cm)	N/A	N/A	HR: 0.55 (p=0.075)	24

An exploratory post-hoc analysis of the GOG-186I data provided intriguing clinical support for the VDA mechanism. The investigators tested the hypothesis that the drug combination would be more effective in patients with larger, bulkier tumors, which are presumed to have more extensive and chaotic vasculature.[24] The results supported this theory: the PFS benefit was substantially more pronounced in patients with tumors larger than the median size of 5.7 cm (HR 0.55) compared to those with smaller tumors (HR 0.77). Although this was an exploratory analysis and not statistically definitive, it suggests that the efficacy of Fosbretabulin is highly context-dependent and may require a specific tumor microenvironment—namely, large tumors with a high degree of vascularization—to exert a meaningful effect.[24] This points toward a potential patient selection strategy but also underscores the drug's limited utility as a broad-spectrum agent.

2.3. Investigations in Other Malignancies

Fosbretabulin has been evaluated in several other solid tumors, generally with limited success.

• Non-Small Cell Lung Cancer (NSCLC): A randomized Phase II study (NCT00653939) investigated the addition of Fosbretabulin to the standard first-line regimen of carboplatin, paclitaxel, and bevacizumab for advanced non-squamous NSCLC.[9] While the four-drug combination was found to have an acceptable toxicity profile, it failed to improve either progression-free or overall survival compared to the standard three-drug regimen.[26] There was a numerically higher overall response rate in the Fosbretabulin arm (50% vs. 32%), but this did not translate into a survival benefit, further highlighting the drug's inability to produce durable responses.[26]
• Neuroendocrine Tumors (NETs): Given their highly vascular nature, NETs are a rational target for anti-vascular therapies. A Phase I trial (NCT03014297) evaluated Fosbretabulin in combination with the mTOR inhibitor everolimus in patients with progressive gastro-entero-pancreatic NETs (GEP-NETs).[27] The study established a recommended Phase II dose and observed stable disease at 3 months in 15 out of 16 evaluable patients, suggesting a degree of clinical activity that warranted further investigation.[27]
• Glioblastoma (GBM): There has been interest in evaluating Fosbretabulin for glioblastoma, an aggressive and highly vascular brain tumor. The drug was considered for inclusion in the innovative GBM AGILE (NCT03970447) adaptive platform trial, which is designed to efficiently test multiple therapies in newly diagnosed and recurrent GBM.[29] This indicates that despite its setbacks, the unique mechanism of Fosbretabulin continues to hold some appeal for specific, hard-to-treat cancers characterized by abnormal vasculature.

Section 3: Comprehensive Safety and Tolerability Assessment

The safety profile of Fosbretabulin is a critical component of its overall clinical story. The drug's primary dose-limiting toxicities are not idiosyncratic or off-target effects but are rather a direct and predictable pharmacological consequence of its potent, on-target vascular-disrupting mechanism. This inextricable link between efficacy and toxicity results in a narrow therapeutic window that has profound implications for its clinical utility, patient selection, and potential for use in combination regimens.

3.1. Integrated Adverse Event Profile

Phase I dose-escalation studies established that Fosbretabulin is generally tolerated, with the vast majority (95%) of treatment-emergent adverse events (AEs) being of mild-to-moderate severity (Grade 0-II).[7] Across numerous clinical trials, a consistent pattern of AEs has emerged, reflecting the drug's systemic impact on vascular physiology.

The most frequently reported drug-related AEs include [7]:

• Cardiovascular: Acute hypertension, QTc interval prolongation, sinus tachycardia, flushing.
• Constitutional: Headache, dizziness, fatigue, diaphoresis.
• Gastrointestinal: Nausea and vomiting.
• Neurological: Vascular vagal excitation (e.g., lightheadedness, presyncope).
• Pain: A characteristic tumor-induced pain, reported by 14.2% of patients in one trial, is thought to arise from the acute ischemic event within the tumor mass following vascular shutdown.[7]

When used in combination with standard cytotoxic chemotherapy, such as carboplatin and paclitaxel, Fosbretabulin has been associated with increased rates of hematological toxicity, specifically neutropenia and leukopenia, compared to the chemotherapy regimen alone.[26]

Table 4: Profile of Common (≥10%) and Serious (Grade ≥3) Adverse Events Associated with Fosbretabulin

Adverse Event	All Grades Incidence (%)	Grade ≥3 Incidence (%)	Notes and Context	Source(s)
Hypertension	29-55%	4-35%	Acute, transient. Incidence and severity are significantly increased when combined with bevacizumab.	14
Headache/Dizziness	~20%	<5%	Common, generally mild to moderate.	7
Tumor-Induced Pain	~14%	<5%	Considered an on-target effect of tumor ischemia.	7
QTc Prolongation	High (up to 75% of patients)	Variable	A significant safety concern requiring ECG monitoring. Correlates with drug dose.	17
Nausea/Vomiting	~10%	<5%	Generally mild and manageable.	7
Fatigue	~15%	<5%	Common constitutional symptom.	16
Neutropenia/Leukopenia	Increased vs. control	Increased vs. control	Primarily observed in combination with chemotherapy.	26

3.2. A Special Focus on Cardiovascular Toxicity

The defining and dose-limiting toxicities of Fosbretabulin are cardiovascular. These effects are a direct manifestation of the drug's powerful and acute impact on the vascular system.

3.2.1. Hypertension

Acute hypertension is the most consistent and clinically significant AE associated with Fosbretabulin.[14] The effect is characteristically transient and biphasic. Following intravenous infusion, blood pressure begins to rise within 30 to 60 minutes, peaks approximately 1 to 2 hours post-dose, and typically returns to baseline levels within 4 to 7 hours.[7] This hemodynamic response is believed to be a systemic reaction to the widespread endothelial cell disruption and release of vasoactive mediators.

The severity of this hypertension is exacerbated when Fosbretabulin is combined with bevacizumab, an agent known to cause sustained hypertension through its inhibition of VEGF signaling. In the GOG-186I trial, the rate of Grade 3 or higher hypertension was nearly doubled in the combination arm (35%) compared to the bevacizumab monotherapy arm (16-20%).[14] This synergistic toxicity necessitates vigilant blood pressure monitoring during and after infusion and careful patient selection.

3.2.2. QTc Interval Prolongation

Fosbretabulin administration is significantly correlated with prolongation of the corrected QT (QTc) interval on electrocardiograms (ECGs).[17] The QTc interval is a measure of the time it takes for the heart's ventricles to repolarize after a heartbeat; significant prolongation is a well-established risk factor for life-threatening cardiac arrhythmias, such as Torsades de Pointes.

In a detailed cardiovascular safety study, significant increases in QTc interval were observed 3 and 4 hours post-infusion.[34] While only a few patients had prolonged QTc intervals at baseline, this number rose to 60-75% of patients after receiving the drug. The magnitude of the QTc increase was directly correlated with the dose of Fosbretabulin administered and the plasma concentration of its active metabolite, CA4.[34] This finding mandates strict cardiac monitoring in clinical trials, including baseline and post-infusion ECGs, and represents a major safety liability.

3.2.3. Ischemic Events

While rare, there have been reports of serious cardiac events. In one study, two patients experienced ECG changes consistent with an acute coronary syndrome within 24 hours of Fosbretabulin infusion.[34] These events underscore the potential for the drug's acute vascular effects to precipitate clinically significant myocardial ischemia, particularly in patients with underlying or undiagnosed coronary artery disease.

3.3. Known and Potential Drug-Drug Interactions

The potential for interactions with other medications is an important consideration for Fosbretabulin's safety profile.

3.3.1. Pharmacodynamic Interactions

• Methemoglobinemia: Drug interaction databases indicate an increased risk of methemoglobinemia—a condition where hemoglobin is unable to release oxygen effectively—when Fosbretabulin is combined with a wide range of local anesthetics (e.g., benzocaine, lidocaine, prilocaine, articaine) and other compounds such as phenol, capsaicin, and dapsone.[2] This is an unusual interaction for an oncology agent and could pose a risk to patients undergoing minor procedures that require local anesthesia, a common occurrence in cancer care.
• Thrombosis: A theoretical risk of increased thrombosis is noted when Fosbretabulin is co-administered with erythropoiesis-stimulating agents like darbepoetin alfa and erythropoietin, likely due to the combined effects on vasculature and blood viscosity.[2]
• Immunosuppression: A potential for increased immunosuppression is listed with the S1P receptor modulator Etrasimod.[2]

3.3.2. Pharmacokinetic Interactions

While formal drug-drug interaction studies are not detailed in the provided materials, clinical trial protocols offer clues about potential pharmacokinetic pathways. The exclusion of patients receiving strong inhibitors or inducers of the cytochrome P450 3A4 (CYP3A4) enzyme system in a trial combining Fosbretabulin with everolimus suggests that Fosbretabulin or its active metabolite CA4 is likely a substrate of this major drug-metabolizing enzyme.[28] Co-administration with strong CYP3A4 inhibitors (e.g., ketoconazole) could increase Fosbretabulin exposure and toxicity, while co-administration with strong inducers (e.g., rifampin) could decrease its efficacy.

Conversely, preclinical data suggest Fosbretabulin can have a positive interaction with certain chemotherapies. One study found that it significantly enhanced the antitumor effect of irinotecan (CPT-11) by increasing the intratumoral concentration of its more potent active metabolite, SN-38.[35]

3.4. Contraindications and Patient Selection Criteria

Based on the known safety profile, particularly the cardiovascular risks, clinical trials for Fosbretabulin have employed strict eligibility criteria. These criteria effectively define the patient populations for whom the drug is contraindicated:

• Significant Cardiovascular Disease: Patients with uncontrolled hypertension (e.g., blood pressure >150/100 mmHg), a recent history (within 6 months) of myocardial infarction or angina, congestive heart failure, or clinically significant cardiac arrhythmias are routinely excluded.[34]
• Baseline ECG Abnormalities: A baseline QTc interval greater than 450 milliseconds is a standard exclusion criterion to mitigate the risk of drug-induced arrhythmias.[34]
• Bleeding Risk: As with other agents that disrupt vascular integrity, caution is advised. Patients with congenital bleeding disorders or those requiring full-dose anticoagulation therapy are often excluded from trials.[37]
• Concomitant Medications: The use of other drugs known to prolong the QTc interval is a key contraindication to avoid additive effects on cardiac repolarization.[36]

Section 4: Regulatory and Developmental Trajectory: A Challenging Path

The journey of Fosbretabulin through the drug development and regulatory process provides a clear reflection of its clinical successes and failures. Despite reaching late-stage clinical trials, the drug remains investigational, and its path has been marked by significant regulatory hurdles, particularly in Europe. This section analyzes its global regulatory status, the strategic implications of its orphan drug designation history, and its overall future outlook.

4.1. Global Regulatory Status

Fosbretabulin has not received marketing approval from any major regulatory agency, including the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA).[9] It is classified as an investigational drug that has progressed to Phase III clinical trials, the final stage before a potential approval application.[1]

4.1.1. United States (FDA)

In the U.S., the development of Fosbretabulin has been advanced under the guidance of the FDA. In 2015, the FDA provided feedback to the sponsor at the time, OXiGENE, supporting the design of a pivotal Phase III trial to evaluate Fosbretabulin in combination with bevacizumab for platinum-resistant ovarian cancer.[22] The agency agreed that progression-free survival (PFS) could serve as the primary endpoint for a registration trial, indicating a potentially viable, though challenging, path to approval.[22]

Furthermore, on December 29, 2015, the FDA granted an Orphan Drug Designation to fosbretabulin tromethamine for the treatment of neuroendocrine tumors.[41] This designation provides incentives such as tax credits and potential market exclusivity to encourage the development of drugs for rare diseases. However, while the designation remains active, the drug has not been approved for this or any other indication.[41]

4.1.2. European Union (EMA)

The regulatory history of Fosbretabulin in the European Union is particularly revealing. The drug was granted orphan designation by the European Commission for three separate rare cancer indications. Orphan designation in the EU is intended for drugs that treat life-threatening or chronically debilitating conditions affecting no more than 5 in 10,000 people and provides benefits such as protocol assistance and a 10-year period of market exclusivity upon approval.[42] Critically, in all three instances, the orphan designation was later withdrawn from the Union Register at the request of the sponsor.

Table 5: Regulatory Milestones and Orphan Drug Designation History

Agency	Action/Designation	Indication	Date Granted	Current Status	Source(s)
FDA (US)	Orphan Drug Designation	Neuroendocrine Tumors	Dec 29, 2015	Designated (Not Approved)	41
EMA (EU)	Orphan Designation	Anaplastic Thyroid Cancer	N/A	Withdrawn (Jul 2021)	44
EMA (EU)	Orphan Designation (EU/3/13/1154)	Ovarian Cancer	Aug 17, 2013	Withdrawn (Sep 2021)	45
EMA (EU)	Orphan Designation (EU/3/16/1633)	Gastro-entero-pancreatic Neuroendocrine Tumours	Mar 21, 2016	Withdrawn (Sep 2021)	46

4.2. Analysis of Orphan Drug Designation Withdrawals

The repeated, voluntary withdrawal of orphan designations in the EU is a strong negative signal regarding the drug's perceived viability. The EMA does not require sponsors to provide a public justification for such requests, leading to a lack of official transparency.[43] However, a strategic analysis based on the regulatory framework and the drug's clinical data provides a compelling explanation.

A key provision of the EU Orphan Regulation is the "significant benefit" clause. At the time of marketing authorization application, if other approved treatments for the condition already exist, the sponsor of the orphan drug must prove that their product offers a significant benefit over these existing therapies.[42] This is a much higher evidentiary bar than that required for the initial designation and necessitates robust comparative clinical data.

The decision to withdraw the designations was likely a pragmatic and strategic one, based on an internal assessment that Fosbretabulin would fail to meet this critical "significant benefit" hurdle.

• For ovarian cancer, the therapeutic landscape evolved significantly during Fosbretabulin's development, with the introduction of highly effective PARP inhibitors and other novel agents. The modest PFS benefit and lack of OS improvement seen in the GOG-186I trial, coupled with the added toxicity of hypertension, would almost certainly not be considered a significant benefit over the new standards of care.[21]
• Similarly, for anaplastic thyroid carcinoma, while options remain limited, the emergence of targeted therapies for BRAF-mutated ATC provided a new benchmark that Fosbretabulin, with its lack of objective responses in its Phase II trial, would struggle to surpass.[17]

By proactively withdrawing the designations, the sponsor avoids a formal negative opinion from the EMA's Committee for Orphan Medicinal Products (COMP), which could have broader negative implications for the program. This pattern of withdrawals is therefore a tacit acknowledgment of the drug's inability to demonstrate competitive efficacy in the modern oncology landscape.

4.3. Concluding Analysis and Future Outlook

Fosbretabulin's development arc exemplifies the classic challenge of translating a novel and potent mechanism of action into a clinically approvable therapeutic. Its journey is defined by a fundamental triad of issues that have collectively stalled its progress:

1. A Narrow Therapeutic Window: The drug's primary dose-limiting cardiovascular toxicities are on-target effects, meaning they are inseparable from its mechanism of action. This creates an inherently narrow therapeutic index where the dose required for efficacy is very close to the dose that causes significant toxicity.
2. Lack of a Definitive Survival Benefit: Despite showing activity in delaying tumor progression (PFS) in some settings, Fosbretabulin has consistently failed to demonstrate an improvement in overall survival, the gold-standard endpoint for cancer drug approval.
3. The "Viable Rim" Limitation: The VDA mechanism's inability to eradicate the entire tumor necessitates combination therapies. However, finding an effective partner drug whose toxicities do not synergize negatively with Fosbretabulin's cardiovascular profile has proven difficult.

Given these substantial challenges, the future viability of Fosbretabulin appears severely limited. A path forward would require a significant strategic pivot away from broad development and toward a highly niche and targeted approach. This could involve:

• Prospective Biomarker Validation: A dedicated effort to validate a predictive biomarker, such as sICAM-1 or a novel genomic or transcriptomic signature, to prospectively identify the small subset of patients who are most likely to derive a substantial and durable benefit.
• Focus on Niche Indications: Concentrating on specific, untreated tumor types where massive, chaotic vascularization is a primary driver of pathology and where few other options exist. The continued interest in its potential for glioblastoma aligns with this strategy.[29]
• Novel Combination Strategies: Exploring combinations with agents that have non-overlapping toxicity profiles, such as certain immunotherapies or targeted agents, that could address the viable rim without exacerbating cardiovascular risk.

Without a clear demonstration of a survival advantage in a well-defined patient population and given its challenging safety profile, Fosbretabulin is unlikely to gain regulatory approval in its current state. It remains a scientifically important compound and a valuable case study in the development of vascular-disrupting agents, but its time as a promising clinical candidate may have passed.

Conclusion

Fosbretabulin (Combretastatin A-4 Phosphate) stands as a testament to both the ingenuity of rational drug design and the formidable challenges of clinical oncology development. Conceived as a clever prodrug to unlock the therapeutic potential of a potent natural product, its dual-pronged mechanism targeting the tumor vasculature represents a distinct and powerful anti-cancer strategy. Preclinical data were exceptionally promising, showcasing an ability to induce rapid and massive tumor necrosis through a swift and selective vascular collapse.

However, the transition from the laboratory to the clinic has been fraught with difficulty. The very potency of its on-target mechanism is the source of its dose-limiting cardiovascular toxicities—acute hypertension and QTc prolongation—creating a narrow therapeutic window that has constrained its clinical utility. Furthermore, the inherent limitation of its mechanism—the survival of a peripheral rim of tumor cells—necessitated a move to combination therapies, which introduced further complexities of efficacy and toxicity.

Across a broad clinical program in multiple cancers, a consistent theme has emerged: despite occasional positive signals in surrogate endpoints like response rate or progression-free survival, Fosbretabulin has failed to deliver the ultimate prize of improved overall survival. The pivotal GOG-186I trial in ovarian cancer, which showed a PFS benefit that did not translate to an OS benefit, encapsulates this core challenge.

The drug's regulatory history, particularly the serial withdrawal of orphan designations in Europe, serves as a clear verdict on its perceived inability to demonstrate a significant benefit over evolving standards of care. Ultimately, Fosbretabulin's story is a cautionary tale. It underscores that a novel mechanism and potent preclinical activity are not guarantees of clinical success. Without a favorable benefit-risk profile and a clear advantage over existing therapies in improving how long patients live, even the most scientifically elegant drug will struggle to find its place in the modern therapeutic armamentarium.

Works cited

1. Fosbretabulin | C18H21O8P | CID 5351387 - PubChem, accessed September 19, 2025, https://pubchem.ncbi.nlm.nih.gov/compound/Fosbretabulin
2. Fosbretabulin: Uses, Interactions, Mechanism of Action | DrugBank Online, accessed September 19, 2025, https://go.drugbank.com/drugs/DB12577
3. Definition of fosbretabulin disodium - NCI Drug Dictionary, accessed September 19, 2025, https://www.cancer.gov/publications/dictionaries/cancer-drug/def/fosbretabulin-disodium
4. fosbretabulin | Ligand page | IUPHAR/BPS Guide to PHARMACOLOGY, accessed September 19, 2025, https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8857
5. Combretastatin A4 Phosphate: A Novel Vascular Disrupting Agent - ResearchGate, accessed September 19, 2025, https://www.researchgate.net/publication/46034188_Combretastatin_A4_phosphate_A_novel_vascular_disrupting_agent
6. Development of Combretastatin A-4 Analogues as Potential Anticancer Agents with Improved Aqueous Solubility - MDPI, accessed September 19, 2025, https://www.mdpi.com/1420-3049/28/4/1717
7. A phase I clinical trial assessing the safety and tolerability of combretastatin A4 phosphate injections | Request PDF - ResearchGate, accessed September 19, 2025, https://www.researchgate.net/publication/260116763_A_phase_I_clinical_trial_assessing_the_safety_and_tolerability_of_combretastatin_A4_phosphate_injections
8. Definition of fosbretabulin tromethamine - NCI Drug Dictionary, accessed September 19, 2025, https://www.cancer.gov/publications/dictionaries/cancer-drug/def/fosbretabulin-tromethamine
9. Fosbretabulin - Wikipedia, accessed September 19, 2025, https://en.wikipedia.org/wiki/Fosbretabulin
10. Combretastatin a-4 – Knowledge and References - Taylor & Francis, accessed September 19, 2025, https://taylorandfrancis.com/knowledge/Medicine_and_healthcare/Pharmaceutical_medicine/Combretastatin_a-4/
11. Fosbretabulin (Combretastatin A4 phosphate) | Vascular Disruptor - MedchemExpress.com, accessed September 19, 2025, https://www.medchemexpress.com/fosbretabulin.html
12. Fosbretabulin (Combretastatin A4 Phosphate) Disodium | Microtubule Associated inhibitor, accessed September 19, 2025, https://www.selleckchem.com/products/fosbretabulin-disodium-combretastatin-a-4-phosphate-disodium-ca4p-disodium.html
13. Fosbretabulin Disodium | Microtubule Associated - TargetMol, accessed September 19, 2025, https://www.targetmol.com/compound/Fosbretabulin%20Disodium
14. Fosbretabulin and Avastin Combo Delays Progression, But Doubles Hypertension in Ovarian Cancer - Cure Today, accessed September 19, 2025, https://www.curetoday.com/view/fosbretabulin-and-avastin-combo-delays-progression-but-doubles-hypertension-in-ovarian-cancer
15. Combretastatin A4 phosphate - PubMed, accessed September 19, 2025, https://pubmed.ncbi.nlm.nih.gov/15014350/
16. A Phase II Trial of Fosbretabulin in Advanced Anaplastic Thyroid ..., accessed September 19, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC2913806/
17. A phase II trial of fosbretabulin in advanced anaplastic thyroid carcinoma and correlation of baseline serum-soluble intracellular adhesion molecule-1 with outcome - PubMed, accessed September 19, 2025, https://pubmed.ncbi.nlm.nih.gov/19265494/
18. Anticancer drug therapy for anaplastic thyroid cancer in - European Thyroid Journal, accessed September 19, 2025, https://etj.bioscientifica.com/view/journals/etj/14/2/ETJ-24-0287.xml
19. Study Details | NCT00060242 | Combretastatin A4 Phosphate in Treating Patients With Advanced Anaplastic Thyroid Cancer | ClinicalTrials.gov, accessed September 19, 2025, https://www.clinicaltrials.gov/study/NCT00060242?term=AREA%5BInterventionSearch%5D(%22Fosbretabulin%22)&rank=4
20. Hypothyroidism to predict for long term survival in patients with fosbretabulin treated anaplastic thyroid carcinoma. - ASCO Publications, accessed September 19, 2025, https://ascopubs.org/doi/10.1200/JCO.2018.36.15_suppl.e18108
21. Randomized Phase II Evaluation of Bevacizumab Versus Bevacizumab Plus Fosbretabulin in Recurrent Ovarian, Tubal, or Peritoneal Carcinoma: An NRG Oncology/Gynecologic Oncology Group Study - ASCO Publications, accessed September 19, 2025, https://ascopubs.org/doi/10.1200/JCO.2015.65.8153
22. OXiGENE Receives Guidance From FDA Supporting Phase III Trial Of Fosbretabulin/Bevacizumab Combination In Platinum-Resistant Ovarian Cancer - BioSpace, accessed September 19, 2025, https://www.biospace.com/oxigene-receives-guidance-from-fda-supporting-phase-iii-trial-of-fosbretabulin-bevacizumab-combination-in-platinum-resistant-ovarian-cancer
23. Study Details | Bevacizumab With or Without Fosbretabulin Tromethamine in Treating Patients With Recurrent or Persistent Ovarian Epithelial, Fallopian Tube, or Peritoneal Cavity Cancer | ClinicalTrials.gov, accessed September 19, 2025, https://www.clinicaltrials.gov/study/NCT01305213?term=NCT01305213&viewType=Table&rank=1
24. BEVACZIUMAB PLUS FOSBRETABULIN IN RECURRENT ..., accessed September 19, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC7789907/
25. Study Results | Bevacizumab With or Without Fosbretabulin ..., accessed September 19, 2025, https://clinicaltrials.gov/study/NCT01305213?tab=results
26. (PDF) A randomized Phase II trial of the tumor vascular disrupting agent CA4P (fosbretabulin tromethamine) with carboplatin, paclitaxel, and bevacizumab in advanced nonsquamous non-small-cell lung cancer - ResearchGate, accessed September 19, 2025, https://www.researchgate.net/publication/311242541_A_randomized_Phase_II_trial_of_the_tumor_vascular_disrupting_agent_CA4P_fosbretabulin_tromethamine_with_carboplatin_paclitaxel_and_bevacizumab_in_advanced_nonsquamous_non-small-cell_lung_cancer
27. Clinical efficacy and toxicity data on phase I study of fosbretabulin in combination with everolimus in neuroendocrine tumors. - ASCO, accessed September 19, 2025, https://www.asco.org/abstracts-presentations/ABSTRACT272025
28. Study Details | NCT03014297 | Fosbretabulin With Everolimus in Neuroendocrine Tumors With Progression | ClinicalTrials.gov, accessed September 19, 2025, https://clinicaltrials.gov/study/NCT03014297
29. Study Details | NCT03970447 | A Trial to Evaluate Multiple Regimens in Newly Diagnosed and Recurrent Glioblastoma | ClinicalTrials.gov, accessed September 19, 2025, https://www.clinicaltrials.gov/study/NCT03970447
30. Treatment Clinical Trials for Glioblastoma - NCI, accessed September 19, 2025, https://www.cancer.gov/research/participate/clinical-trials/disease/glioblastoma/treatment?pn=1
31. A phase I clinical trial assessing the safety and tolerability of combretastatin A4 phosphate injections - PubMed, accessed September 19, 2025, https://pubmed.ncbi.nlm.nih.gov/24500030/
32. A randomized Phase II trial of the tumor vascular disrupting agent CA4 - Dove Medical Press, accessed September 19, 2025, https://www.dovepress.com/a-randomized-phase-ii-trial-of-the-tumor-vascular-disrupting-agent-ca4-peer-reviewed-fulltext-article-OTT
33. Clinical trial experience with CA4P anticancer therapy: focus on efficacy, cardiovascular adverse events, and hypertension management - PMC, accessed September 19, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC5756341/
34. Cardiovascular safety profile of combretastatin a4 phosphate in a single-dose phase I study in patients with advanced cancer - PubMed, accessed September 19, 2025, https://pubmed.ncbi.nlm.nih.gov/14734457/
35. Combretastatin A-4 phosphate enhances CPT-11 activity independently of the administration sequence - PubMed, accessed September 19, 2025, https://pubmed.ncbi.nlm.nih.gov/14728944/
36. NCT01423149 | Safety and Efficacy Study of Combretastatin A4 Phosphate to Treat Patients With Choroidal Neovascularization Secondary to Pathologic Myopia | ClinicalTrials.gov, accessed September 19, 2025, https://clinicaltrials.gov/study/NCT01423149
37. Bevacizumab in the treatment of NSCLC: patient selection and perspectives - PMC, accessed September 19, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC5733913/
38. Collateral damage: toxic effects of targeted antiangiogenic therapies in ovarian cancer, accessed September 19, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC3199129/
39. Oncology (Cancer)/Hematologic Malignancies Approval Notifications - FDA, accessed September 19, 2025, https://www.fda.gov/drugs/resources-information-approved-drugs/oncology-cancerhematologic-malignancies-approval-notifications
40. Cancer Accelerated Approvals - Withdrawn - FDA, accessed September 19, 2025, https://www.fda.gov/drugs/resources-information-approved-drugs/withdrawn-cancer-accelerated-approvals
41. Search Orphan Drug Designations and Approvals - FDA, accessed September 19, 2025, https://www.accessdata.fda.gov/scripts/opdlisting/oopd/detailedIndex.cfm?cfgridkey=500715
42. Impact of first-to-market product on orphan designation status for subsequent products in the EU4, accessed September 19, 2025, https://globalpricing.com/impact-of-first-to-market-product-on-orphan-designation-status-for-subsequent-products-in-the-eu4/
43. Removal of the EMA orphan designation upon request of the sponsor: cui prodest?, accessed September 19, 2025, https://www.researchgate.net/publication/348804538_Removal_of_the_EMA_orphan_designation_upon_request_of_the_sponsor_cui_prodest
44. EU/3/04/195 - orphan designation for treatment of anaplastic thyroid ..., accessed September 19, 2025, https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-04-195
45. EU/3/13/1154 - orphan designation for treatment of ovarian cancer ..., accessed September 19, 2025, https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-13-1154
46. EU/3/16/1633 - orphan designation for treatment of gastro-entero-pancreatic neuroendocrine tumours | European Medicines Agency (EMA), accessed September 19, 2025, https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-16-1633
47. Removal of the EMA orphan designation upon request of the sponsor: cui prodest?, accessed September 19, 2025, https://pubmed.ncbi.nlm.nih.gov/33501508/